Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ethnic differences in pharmacogenetically relevant genes.

R M Engen1, S Marsh, D J Van Booven

  • 1Department of Medicine, Washington University School of Medicine and The Siteman Cancer Center, St Louis, Missouri 63110, USA.

Current Drug Targets
|December 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on the management of patients with HIV infection in anaesthesia and critical care.

BJA education·2023
Same author

Perioperative considerations for transgender and gender diverse adults.

BJA education·2023
Same author

<i>In vitro</i> Exposure to Inflammatory Mediators Affects the Differentiation of Mesenchymal Progenitors.

Frontiers in bioengineering and biotechnology·2022
Same author

Dermatological complications of critical care.

BJA education·2021
Same author

Life-threatening skin conditions presenting to critical care.

BJA education·2021
Same author

Steroid use in critical care.

BJA education·2021
Same journal

Extracellular Vesicles from Mesenchymal Stem Cells Alleviate Spinal Cord Injury via the miR-486-5p/PTEN/PI3K/AKT Pathway.

Current drug targets·2026
Same journal

Improving B-cell Linear Epitope Prediction <i>via</i> Multiple Feature Fusion and an Integrated Machine Learning Algorithm.

Current drug targets·2026
Same journal

Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis.

Current drug targets·2026
Same journal

Epitranscriptomics in Breast Cancer: The Unveiled Role of RNA Modifications.

Current drug targets·2026
Same journal

Neuroinflammation in Alzheimer's Disease: New Approaches.

Current drug targets·2026
Same journal

FXYD3: A Key Regulator of Ion Homeostasis and Redox Balance in Cancer Biology.

Current drug targets·2026
See all related articles

Human drug response varies significantly due to genetic differences. Understanding pharmacogenomics across diverse populations is key to optimizing personalized medicine and improving global patient outcomes.

Area of Science:

  • Pharmacogenomics
  • Genetics
  • Drug Metabolism

Background:

  • Individual responses to medications show significant variability.
  • Genetic variations in drug targets and metabolizing enzymes influence treatment efficacy and toxicity.
  • Current strategies for drug selection are often empirical, necessitating personalized approaches.

Purpose of the Study:

  • To highlight the impact of genetic polymorphisms on drug response.
  • To emphasize the role of ethnicity in pharmacogenomic variations.
  • To advocate for genome-guided therapy optimization worldwide.

Main Methods:

  • Analysis of genetic polymorphisms in drug-metabolizing enzymes, transporters, and receptors.
  • Comparison of allele frequencies and specific mutations across different population groups.

Related Experiment Videos

  • Examination of ethnic variations in pharmacogenomic markers, such as thiopurine methyltransferase (TPMT).

    • Main Results:

    • Genetic polymorphisms serve as predictive markers for drug toxicity and treatment failure.
    • Significant quantitative and qualitative differences in polymorphic genes exist between populations.
    • Ethnic variations in TPMT mutations (e.g., TPMT*13C in Chinese vs. TPMT*3A in Caucasians) impact enzyme activity.

    Conclusions:

    • Ethnic differences in pharmacogenomics are substantial and influence drug response.
    • Incorporating ethnic considerations into pharmacogenomic strategies is crucial.
    • A global approach to genome-guided therapy can optimize treatment for diverse patient populations.